Adverum Biotechnologies faces securities fraud investigation after financial restatements, stock price drops.

From Financial Modeling Prep: 2025-04-03 14:00:00

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) faces an investigation by Pomerantz LLP for potential securities fraud after revealing financial restatements due to non-cash errors. The stock price dropped by 12.36% to $3.83 on April 1, 2025.

Despite the probe, insider Leonard Braden Michael’s significant purchases of ADVM shares indicate confidence in the company’s recovery. He acquired over 15,000 shares at around $4.04 each on April 2, 2025, and previously bought 19,566 shares at $4.38 each on March 31, 2025.

Adverum’s financial metrics show profitability and cash flow challenges, with negative P/E and earnings yield ratios. The company is undervalued based on price-to-sales ratios, reflecting market concerns over sales performance. However, a strong current ratio of 5.82 suggests good short-term financial health and liquidity.

The enterprise value to operating cash flow ratio of -0.73 indicates difficulties in generating positive cash flow from operations. Adverum’s debt-to-equity ratio of 0.51 shows a moderate level of debt compared to equity, indicating a balanced financial structure. Investors will monitor the company’s actions and financial performance closely amid ongoing investigations.



Read more at Financial Modeling Prep:: Adverum Biotechnologies Faces Investigation and Fi…